Relationship of Patient Age to Pathologic Features of the Tumor and Prognosis for Patients with Stage I or II Breast Cancer
Overview
Authors
Affiliations
Purpose: This analysis was performed to clarify the relationship of young age at diagnosis to the pathologic features of the tumor and prognosis in patients with early-stage breast cancer.
Patients And Methods: We retrospectively analyzed data from 1,398 patients with American Joint Committee on Cancer Staging stage I or II breast cancer treated by breast-conserving therapy between 1968 and 1985. One hundred seven patients were younger than 35 years at the time of diagnosis. The median follow-up duration for the 1,032 survivors was 99 months.
Results: Patients younger than 35 years had a significantly higher overall recurrence rate (P = .002), as well as a greater risk for developing distant metastases (P = .03), when compared with older patients. The cancers in younger patients more commonly showed factors associated with a worse prognosis (including grade 3 histology, lymphatic vessel invasion [LVI], necrosis, and estrogen receptor [ER] negativity) as compared with older patients. In a proportional hazards model that included clinical and treatment-related variables, as well as these pathologic features, age younger than 35 years remained a significant predictor for time to recurrence (relative risk [RR], 1.70), time to distant failure (RR, 1.60), and overall mortality (RR, 1.50).
Conclusion: Breast cancer patients younger than 35 years have a worse prognosis than older patients. This difference is only partially explained by a higher frequency of adverse pathologic factors seen in younger patients.
Age and Late Recurrence in Young Patients With ER-Positive, ERBB2-Negative Breast Cancer.
Shin D, Lee J, Kang E, Noh D, Cheun J, Lee J JAMA Netw Open. 2024; 7(11):e2442663.
PMID: 39509133 PMC: 11544499. DOI: 10.1001/jamanetworkopen.2024.42663.
Nair N, Ali B, Siddique S, Maheshwari A, Bajpai J, Parmar V South Asian J Cancer. 2024; 13(3):215-219.
PMID: 39410988 PMC: 11473132. DOI: 10.1055/s-0043-1771385.
Zeng Q, Han L, Hong Q, Wang G, Xue X, Fang Y Heliyon. 2024; 10(14):e33794.
PMID: 39100449 PMC: 11295570. DOI: 10.1016/j.heliyon.2024.e33794.
Survival pattern in male breast cancer: distinct from female breast cancer.
Gwark S, Kim J, Chung I, Kim H, Ko B, Lee J Front Oncol. 2024; 14:1392592.
PMID: 39007102 PMC: 11239393. DOI: 10.3389/fonc.2024.1392592.
Apostolou P, Dellatola V, Papathanasiou A, Kalfakakou D, Fountzilas E, Tryfonopoulos D Cancers (Basel). 2024; 16(13).
PMID: 39001430 PMC: 11240773. DOI: 10.3390/cancers16132368.